3-(2-乙氧基乙氧基)苯甲酸 | 898747-62-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-乙氧基乙氧基)苯甲酸
• 中文别名: 3-(2-二乙氧基)苯甲酸
• 英文名称: 3-(2-ethoxy-ethoxy)-benzoic acid
• 英文别名: 3-(2-Aethoxy-aethoxy)-benzoesaeure；3-(2-Ethoxyethoxy)benzoic acid
• CAS: 898747-62-1
• 化学式: C₁₁H₁₄O₄
• mdl: MFCD08559379
• 分子量: 210.23
• InChiKey: PDBRKLANBVKFLK-UHFFFAOYSA-N

物化性质

• 熔点：
  77.5-78.5 °C
• 沸点：
  361.4±22.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(2-乙氧基乙氧基)苯甲酸 、 1-(3-氨基)-4-(2-甲氧基苯基)哌嗪 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以94%的产率得到3-(2-ethoxyethoxy)-N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]benzamide
  参考文献：
  名称：

  Bivalent molecular probes for dopamine D2-like receptors

  摘要：

  Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D-2-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D-2long, D-2short, D-3 and D-4 receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D-3 subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1 equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.063
• 作为产物：
  描述：

  3-羟基苯甲酸甲酯 在 potassium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 3-(2-乙氧基乙氧基)苯甲酸
  参考文献：
  名称：

  Bivalent molecular probes for dopamine D2-like receptors

  摘要：

  Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D-2-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D-2long, D-2short, D-3 and D-4 receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D-3 subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1 equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.10.063

文献信息

• [EN] MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE<br/>[FR] MODULATEURS DE L'HÉMOGLOBINE POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2020072377A1

  公开（公告）日：2020-04-09

  The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.

  本公开涉及一般式（I）化合物及含有它们的药物组合物。这些化合物适用作血红蛋白调节剂，因此在治疗由血红蛋白介导的疾病如镰状细胞病中有用。
• Substituted phenylimidazopyrazoles and their use
  申请人：BAYER INTELLECTUAL PROPERTY GmbH

  公开号：US20130190290A1

  公开（公告）日：2013-07-25

  The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新颖的1-苯基-1H-咪唑[1,2-b]吡唑衍生物，其制备方法，其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病的药物，特别是血管生成障碍和过度增殖障碍，其中血管新生起到作用，例如肿瘤性疾病和肿瘤性疾病。这种治疗可以作为单独治疗，也可以与其他药物或其他治疗措施结合使用。
• SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF
  申请人：Bayer Intellectual Property GmbH

  公开号：US20150005288A1

  公开（公告）日：2015-01-01

  The present application relates to novel 1-phenyl-1H-imidazo[1,2-b]pyrazole derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular angiogenic disorders and hyperproliferative disorders, where neovascularization plays a role, such as, for example, neoplastic disorders and tumour disorders. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型1-苯基-1H-咪唑[1,2-b]吡唑衍生物，其制备过程，其用于治疗和/或预防疾病以及其用于制备治疗和/或预防疾病的药物，特别是血管生成障碍和增生性疾病，其中新生血管化起到作用，例如肿瘤性疾病和肿瘤性疾病。这种治疗可以作为单一疗法进行，也可以与其他药物或进一步治疗措施结合使用。
• SUBSTITUIERTE PHENYLIMIDAZOPYRAZOLE UND IHRE VERWENDUNG
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2807162B1

  公开（公告）日：2017-06-07
• MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE
  申请人：Global Blood Therapeutics, Inc.

  公开号：EP3860975A1

  公开（公告）日：2021-08-11